{"altmetric_id":2007784,"counts":{"readers":{"mendeley":173,"citeulike":0,"connotea":1},"facebook":{"unique_users_count":1,"unique_users":["257689304383291"],"posts_count":1},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1},"total":{"posts_count":2}},"citation":{"abstract":"Patients with severe persistent asthma who are inadequately controlled despite Global Initiative for Asthma (GINA) 2002 step 4 therapy are a challenging population with significant unmet medical need. We determined the effect of omalizumab on clinically significant asthma exacerbations (requiring systemic corticosteroids) in the first omalizumab study to exclusively enrol patients from this difficult-to-treat patient population.","abstract_source":"pubmed","altmetric_jid":"4f6fa4e83cf058f6100021d3","authors":["M Humbert","R Beasley","J Ayres","R Slavin","J H\u00e9bert","J Bousquet","K-M Beeh","S Ramos","G W Canonica","S Hedgecock","H Fox","M Blogg","K Surrey","Humbert, M.","Beasley, R.","Ayres, J.","Slavin, R.","H\u00e9bert, J.","Bousquet, J.","Beeh, K.\u2010M.","Ramos, S.","Canonica, G. W.","Hedgecock, S.","Fox, H.","Blogg, M.","Surrey, K."],"doi":"10.1111\/j.1398-9995.2004.00772.x","endpage":"316","first_seen_on":"2013-12-28T01:08:00+00:00","handles":[],"isbns":[],"issns":["0105-4538","01054538","13989995","1398-9995"],"issue":"3","journal":"Allergy","last_mentioned_on":1459728000,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15679715","http:\/\/dx.doi.org\/10.1111\/j.1398-9995.2004.00772.x"],"pdf_url":"http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2004.00772.x\/pdf","pmid":"15679715","pubdate":"2005-03-01T00:00:00+00:00","publisher":"Munksgaard International Publishers","publisher_subjects":[{"name":"Immunology","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Immunology and Microbiology"],"startpage":"309","subjects":["allergyandimmunology"],"title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.","type":"article","volume":"60","mendeley_url":"http:\/\/www.mendeley.com\/research\/benefits-omalizumab-addon-therapy-patients-severe-persistent-asthma-inadequately-controlled-despite-1"},"altmetric_score":{"score":3.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3.25},"context_for_score":{"all":{"total_number_of_other_articles":7762368,"mean":6.6348441760037,"rank":1822655,"this_scored_higher_than_pct":76,"this_scored_higher_than":5904440,"rank_type":"exact","sample_size":7762368,"percentile":76},"similar_age_3m":{"total_number_of_other_articles":179655,"mean":7.0654592049164,"rank":43265,"this_scored_higher_than_pct":75,"this_scored_higher_than":135509,"rank_type":"exact","sample_size":179655,"percentile":75},"this_journal":{"total_number_of_other_articles":2043,"mean":8.6335543584721,"rank":892,"this_scored_higher_than_pct":55,"this_scored_higher_than":1125,"rank_type":"exact","sample_size":2043,"percentile":55},"similar_age_this_journal_3m":{"total_number_of_other_articles":30,"mean":7.7563448275862,"rank":22,"this_scored_higher_than_pct":23,"this_scored_higher_than":7,"rank_type":"exact","sample_size":30,"percentile":23}}},"demographics":{"users":{"mendeley":{"by_status":{"Unspecified":1,"Professor > Associate Professor":13,"Researcher":40,"Student  > Doctoral Student":9,"Student  > Ph. D. Student":17,"Student  > Postgraduate":14,"Student  > Master":17,"Other":34,"Student  > Bachelor":15,"Lecturer":1,"Lecturer > Senior Lecturer":2,"Professor":10},"by_discipline":{"Medicine and Dentistry":125,"Physics and Astronomy":1,"Mathematics":1,"Unspecified":5,"Pharmacology, Toxicology and Pharmaceutical Science":3,"Engineering":1,"Chemistry":2,"Economics, Econometrics and Finance":5,"Immunology and Microbiology":2,"Agricultural and Biological Sciences":20,"Computer Science":2,"Business, Management and Accounting":1,"Nursing and Health Professions":1,"Biochemistry, Genetics and Molecular Biology":4}}},"geo":{"mendeley":{"CA":2,"BE":1,"BR":2,"DK":2,"GB":3,"IT":1,"FR":1,"AU":1,"CH":1,"PT":1}}},"posts":{"facebook":[{"title":"Benefits of omalizumab as add-on therapy in patients... [Allergy. 2005] - PubMed - NCBI","url":"https:\/\/www.facebook.com\/257689304383291\/posts\/260365130782375","license":"public","citation_ids":[2007784],"posted_on":"2013-12-28T00:56:03+00:00","summary":"\u4eca\u65e5\u306f\u30b8\u30e3\u30fc\u30ca\u30eb\u30af\u30e9\u30d6\u306e\u65e5\u3067\u3057\u305f\uff01\n\n\n\u8ad6\u6587\uff1a http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15679715\n\n\n\n\u30c1\u30a7\u30c3\u30af\u30b7\u30fc\u30c8\nhttp:\/\/caspjp.umin.ac.jp\/caspjpe\/page55\/files\/RCT21j.pdf\n\n\nA\u3000\u3053\u306e\u8a66\u9a13\u306e\u7d50\u679c\u306f\u4fe1\u983c\u3067\u304d\u308b\u304b\n\u2460\u305d\u306e\u8a66\u9a13\u306f\u7126\u70b9\u304c\u660e\u78ba\u306a\u8ab2\u984c\u8a2d\u5b9a\u304c\u3055\u308c\u3066\u3044\u308b\u304b\n\u60a3\u8005\uff1a inclusion\u3000\n\u30d7\u30ea\u30c3\u30af\u30c6\u30b9\u30c8\u3067\u30be\u30ec\u30a2\u967d\u6027\u306f\u9664\u5916,IgE\uff1a30-700\n1000\u03bcg\/day\u306eBDP or\u3000LABA\u304c\u5fc5\u8981\u306a\u91cd\u75c7\u5598\u606f\nFEV","author":{"name":"\u6d1b\u548c\u4f1a\u4e38\u592a\u753a\u75c5\u9662\u3000\u6551\u6025\u30fb\u7dcf\u5408\u8a3a\u7642\u79d1","url":"https:\/\/www.facebook.com\/257689304383291","facebook_wall_name":"\u6d1b\u548c\u4f1a\u4e38\u592a\u753a\u75c5\u9662\u3000\u6551\u6025\u30fb\u7dcf\u5408\u8a3a\u7642\u79d1","image":"https:\/\/graph.facebook.com\/257689304383291\/picture","id_on_source":"257689304383291"}}],"policy":[{"title":"Mepolizumab for treating severe refractory eosinophilic asthma: Committee papers","url":"https:\/\/www.nice.org.uk\/guidance\/TA431\/documents\/committee-papers","license":"public","citation_ids":[2601871,11852846,20518340,1978093,2623308,2287974,257182,20518341,1312598,8259603,3835140,4287494,1266136,892437,2171954,2669988,2670769,20518450,561821,4670307,9689534,16020327,2007784,20518346,16020173,5617284,20518347,20518348,2601853,1346601,1940980,2804613,2601888,11846985,2601855,20518351,2412361,1249826,21203497,2623308,15775677,2439115,2412361,2601879,20518352,20518356,2413152,2601872,20518360,5349310,12145959,1871021,2601909,13722742,20518363,20518366,213080,2601889,2601912,2492067,1919457,2413174,173441,4113246,1092998,2432094,2323619,3306212,2473422,20518396,20518402,20518405,2601859,2601908,2488145,935260,2601873,20518420,1366825,20518431,2865504,1301370,1587282,15748393,20518438,1647833,925901,1156904,20518446,20518447,20518449,15459606,16862678,3668432,540965,231427,523037,20518450,4021823,2234722,20518452,2601887,20518453,2601915,1390320,745809,2601856,2488113,1950702,2242593,1132541,1964009,1203500,2601878,225580,485909,669591,3294845,2601890,1843267,3283604,20518458,20518462,2601900,20518464,718948,603675,2601865,2601893,2601910,1367263,20518465,1384591,20518466,20518467,2601894,719730,1346601,20518468,2601911,2670769,4670307,2669989,561821,20454255,10950963,135436,513580,20518472,4475148,20518473,2171954,892437,7421135,13678750,20518474,20518475,525698,2672029,2601881,616294,2428440,1721563,2287974,2669988,2954756,1569397,3835140,20518478,527744,20518488,14991456,2999559,20518490,20518491,1681976,20518494,20518497,892437,20518498,19036521,20518504,1127154,20518510,20518511,19036521,11852846,3835140,2669988,19036521,2670769,20518450,561821,4670307,2804613,11846985,20518351,1249826,3668432,3668432],"posted_on":"2016-04-04T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta431\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-3abf693d514ea204d4a96611466361f71990b72a8657d73bdb606648481c94a4.jpg"}}]}}